Newamsterdam Pharma CO NV 8-K filings

NewAmsterdam Pharma Company N.V. amends prior filing to detail separation and advisory agreements for former COO Douglas Kling.

NewAmsterdam Pharma announced a positive CHMP opinion recommending marketing authorization for its cardiovascular treatments, obicetrapib and obicetrapib/ezetimibe, alongside its second-quarter financial results.

NewAmsterdam Pharma and Menarini Group announced a positive opinion from the EMA's CHMP recommending marketing authorization for Ubeslo and Evlarco, key treatments for cardiovascular disease.

NewAmsterdam Pharma's Chief Operating Officer, Douglas Kling, is resigning to become CEO of another clinical-stage biotech company, effective August 14, 2026.

NewAmsterdam Pharma Company N.V. announced shareholder approval of the 2026 Employee Stock Purchase Plan and re-appointment of directors at its annual general meeting.

NewAmsterdam Pharma reported Q1 2026 financial results, highlighting progress in obicetrapib clinical trials and maintaining a strong cash position.

NewAmsterdam Pharma Company N.V. announced the departure of Chief Accounting Officer Louise Kooij effective August 31, 2026.

NewAmsterdam Pharma released an updated investor presentation highlighting positive clinical trial data for obicetrapib in cardiometabolic diseases and Alzheimer's, alongside strong financial positioning.

NewAmsterdam Pharma reported approximately $729 million in cash, cash equivalents, and marketable securities as of December 31, 2025, while outlining key clinical development progress and strategic priorities for 2026.

NewAmsterdam Pharma announced its third-quarter 2025 financial results and provided corporate updates, including EMA acceptance of obicetrapib applications and ongoing clinical trial progress.

NewAmsterdam Pharma presented compelling clinical data for obicetrapib in cardiometabolic diseases and promising Alzheimer's biomarker results, with EMA submission targeted for late 2025.

NewAmsterdam Pharma announced the European Medicines Agency has validated the Marketing Authorization Application for obicetrapib, advancing its potential approval for hypercholesterolemia.

NewAmsterdam Pharma's subsidiary entered a Supply Agreement with Menarini to provide obicetrapib drug products, initially as an exclusive supplier.

NewAmsterdam Pharma announced its second quarter 2025 financial results and provided corporate updates, highlighting progress in obicetrapib's clinical development and a strong cash position.

NewAmsterdam Pharma announced positive full data from a prespecified Alzheimer's disease biomarker analysis within its Phase 3 BROADWAY clinical trial, demonstrating statistically significant reductions in key AD pathology markers, particularly in high-risk ApoE4 carriers.

NewAmsterdam Pharma Company N.V. has amended the employment agreement for its Chief Scientific Officer and director, Dr. John Kastelein, detailing severance and equity acceleration provisions.

NewAmsterdam Pharma presented compelling clinical data for its lead product candidate, Obicetrapib, highlighting its potential in both cardiovascular disease and Alzheimer's, alongside a robust commercial strategy and strong financial position.

NewAmsterdam Pharma announced positive topline data from its Phase 3 BROADWAY clinical trial, demonstrating that obicetrapib significantly reduced Alzheimer's disease biomarkers, particularly in ApoE4 carriers.

NewAmsterdam Pharma Company N.V. announced that all nine proposals, including the adoption of 2024 annual accounts, director appointments, and auditor selections, were approved by shareholders at its 2025 Annual General Meeting.

NewAmsterdam Pharma announces its Q1 2025 financial results, highlighting a strong cash position and continued clinical development of obicetrapib.

NewAmsterdam Pharma's obicetrapib demonstrates significant LDL-C and Lp(a) reductions in Phase 3 trials, with data published in The New England Journal of Medicine and The Lancet.

NewAmsterdam Pharma appoints Adele Gulfo, a seasoned pharmaceutical executive, to its Board of Directors to leverage her commercial expertise as the company prepares for the potential launch of obicetrapib.

NewAmsterdam Pharma announces full year 2024 financial results, highlighting a strong cash position and progress in clinical development of obicetrapib.

NewAmsterdam Pharma reports positive results from three Phase 3 trials in 2024 and outlines strategic priorities for 2025, including regulatory filings and commercial readiness for obicetrapib.

NewAmsterdam Pharma successfully completed a public offering, raising approximately $452.6 million through the sale of ordinary shares and pre-funded warrants.

NewAmsterdam Pharma has suspended and terminated its $150 million at-the-market offering of ordinary shares, effective December 10, 2024.

NewAmsterdam Pharma's Phase 3 BROADWAY trial demonstrated a statistically significant 33% reduction in LDL-C with obicetrapib, along with a 21% observed reduction in major adverse cardiovascular events.

NewAmsterdam Pharma's Phase 3 TANDEM trial demonstrated that a fixed-dose combination of obicetrapib and ezetimibe significantly reduced LDL-C levels in patients with high cardiovascular risk.

NewAmsterdam Pharma released additional positive data from its Phase 3 BROOKLYN trial, showing significant reductions in LDL-C and other key lipid markers with obicetrapib.

NewAmsterdam Pharma reports faster than expected enrollment in a key trial, leading to an earlier data release, and a strong cash position.